TY - JOUR
T1 - Vagal effects of endocrine HPA axis challenges on resting autonomic activity assessed by heart rate variability measures in healthy humans
AU - Agorastos, Agorastos
AU - Heinig, Alexandra
AU - Stiedl, Oliver
AU - Hager, Torben
AU - Sommer, Anne
AU - Müller, Jana C.
AU - Schruers, Koen R.
AU - Wiedemann, Klaus
AU - Demiralay, Cüneyt
PY - 2019/4
Y1 - 2019/4
N2 -
Background: The hypothalamic-pituitary-adrenal axis (HPA axis) and the autonomic nervous system (ANS) are considered to play the most crucial role in the pathophysiology of stress responsiveness and are increasingly studied together. However, only few studies have simultaneously assessed HPA axis and ANS activity to investigate their direct interaction in pathophysiology, while no study so far has assessed the dynamic interplay between the two systems in healthy subjects through endocrine challenges. Methods: The present study assessed the direct effects of overnight pharmacoendocrine HPA axis challenges with dexamethasone (suppression) and metyrapone (stimulation) on ANS activity at rest as determined by linear and nonlinear measures of heart rate variability (HRV) in 39 young healthy individuals. Results: Findings indicated significant effects of metyrapone, but not dexamethasone on autonomic activity at rest based on HRV measures. HRV after metyrapone was overall significantly reduced in comparison to baseline or post-dexamethasone conditions, while the combined metyrapone-related reduction of HRV measures RMSSD, NN50(%) and HF(%) with concomitant increase of the unifractal scaling coefficient α
fast
value jointly indicated a specifically diminished vagal activity. Conclusions: We provide first data that HPA axis stimulation (metyrapone) is associated with reduced vagal tone, while HPA axis suppression (dexamethasone) has no effect on autonomic modulation of heart function. Our results support a vital role of the parasympathetic nervous system in the interplay between ANS and HPA axis and, thus, in the modulation of stress-related cardiovascular responsiveness and the susceptibility to stress-related disorders.
AB -
Background: The hypothalamic-pituitary-adrenal axis (HPA axis) and the autonomic nervous system (ANS) are considered to play the most crucial role in the pathophysiology of stress responsiveness and are increasingly studied together. However, only few studies have simultaneously assessed HPA axis and ANS activity to investigate their direct interaction in pathophysiology, while no study so far has assessed the dynamic interplay between the two systems in healthy subjects through endocrine challenges. Methods: The present study assessed the direct effects of overnight pharmacoendocrine HPA axis challenges with dexamethasone (suppression) and metyrapone (stimulation) on ANS activity at rest as determined by linear and nonlinear measures of heart rate variability (HRV) in 39 young healthy individuals. Results: Findings indicated significant effects of metyrapone, but not dexamethasone on autonomic activity at rest based on HRV measures. HRV after metyrapone was overall significantly reduced in comparison to baseline or post-dexamethasone conditions, while the combined metyrapone-related reduction of HRV measures RMSSD, NN50(%) and HF(%) with concomitant increase of the unifractal scaling coefficient α
fast
value jointly indicated a specifically diminished vagal activity. Conclusions: We provide first data that HPA axis stimulation (metyrapone) is associated with reduced vagal tone, while HPA axis suppression (dexamethasone) has no effect on autonomic modulation of heart function. Our results support a vital role of the parasympathetic nervous system in the interplay between ANS and HPA axis and, thus, in the modulation of stress-related cardiovascular responsiveness and the susceptibility to stress-related disorders.
KW - Autonomic nervous system
KW - Cortisol
KW - Dexamethasone
KW - Endocrine challenge
KW - Heart rate variability
KW - Hypothalamus-pituitary-adrenal axis (HPA axis)
KW - Metyrapone
KW - Stress
KW - Vagus
UR - http://www.scopus.com/inward/record.url?scp=85058662109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058662109&partnerID=8YFLogxK
U2 - 10.1016/j.psyneuen.2018.12.017
DO - 10.1016/j.psyneuen.2018.12.017
M3 - Article
C2 - 30579237
AN - SCOPUS:85058662109
SN - 0306-4530
VL - 102
SP - 196
EP - 203
JO - Psychoneuroendocrinology
JF - Psychoneuroendocrinology
ER -